Story perspectives

Pharma Stocks Swing: Maze Soars, Soleno Plummets Amid Safety Concerns

9/13/2025

49 3

Summary

Story summary

Maze Therapeutics' shares surged over 50% following positive Phase 1 results for MZE782, a phenylketonuria treatment, with no severe adverse events reported.
Intercept Pharmaceuticals will withdraw its liver disease drug Ocaliva from the U.S. market due to FDA safety concerns.
Soleno Therapeutics' stock fell nearly 20% after a patient death linked to its drug Vykat, although the company stated no connection.
Arrowhead Pharmaceuticals faces a patent dispute with Ionis Pharmaceuticals regarding drugs for familial chylomicronemia syndrome.
Merck's pneumococcal vaccine Capvaxive demonstrated strong immune responses in at-risk children and teens.
A child died after receiving experimental gene therapy from Capsida Biotherapeutics for STXBP1 encephalopathy.

1 of 1

Story summary

Maze Therapeutics' shares surged over 50% following positive Phase 1 results for MZE782, a phenylketonuria treatment, with no severe adverse events reported.
Intercept Pharmaceuticals will withdraw its liver disease drug Ocaliva from the U.S. market due to FDA safety concerns.
Soleno Therapeutics' stock fell nearly 20% after a patient death linked to its drug Vykat, although the company stated no connection.
Arrowhead Pharmaceuticals faces a patent dispute with Ionis Pharmaceuticals regarding drugs for familial chylomicronemia syndrome.
Merck's pneumococcal vaccine Capvaxive demonstrated strong immune responses in at-risk children and teens.
A child died after receiving experimental gene therapy from Capsida Biotherapeutics for STXBP1 encephalopathy.